JM
Therapeutic Areas
Genfit Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Elafibranor (GFT505) | Primary Biliary Cholangitis (PBC) | Phase 3 |
| NIS4® Technology | Diagnosis of at-risk NASH (F≥2) | Commercial |
Leadership Team at Genfit
PP
Pascal Prigent
Chief Executive Officer
DH
Dean Hum
Chief Scientific Officer
SM
Sophie Mégnien
Chief Medical Officer
ND
Nicolas Decourt
Chief Business Officer
LD
Laurent de Narbonne
Chief Commercial Officer
YB
Yannick Borsu
Chief Financial Officer
KB
Katherine B. McCarthy
Independent Director, Board Member
SM
Susan M. Byrne
Independent Director, Board Member
BL
Bénédicte Lallemand
Independent Director, Board Member
LL
Lucie Larguier
SVP, General Counsel & Corporate Secretary